Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk

Breast tumors exhibit extensive molecular and clinical heterogeneity. One of the most utilized breast carcinoma classifications is based on its molecular aspects and subdivides breast cancer into five major groups based on the expression of certain genes. In this study, we evaluated which factors are important in determining a prognosis after 5 years of follow-up for patients with clinical stage IIA breast tumors. We took into consideration the different phenotypes (luminal A luminal B HER-2 overexpression, basal and triple-negative), various epithelial-mesenchymal (EMT) molecular markers and adhesion molecules (E-cadherin, P-cadherin, N-cadherin, vimentin, twist snail and slug) and NOS-2, in addition to clinical and demographic data, tumor characteristics and treatment types. METHODS: The study population consisted of 82 patients with breast cancer. We analyzed eight molecular markers by immunohistochemistry on tissue microarrays containing breast tumor specimens from patients with ten years of follow-up, and we classified each tumor according to its estrogen receptor, progesterone receptor and HER-2 expression. We then placed the tumor into one of the above categories. RESULTS: The presence of several clinical and demographic factors, various histopathologies, treatment forms and several immunohistochemical markers were not associated with a worse prognosis for group IIA patients. The factors that were associated with a mortality risk were the triple-negative (odds ratio (OR) = 11.8, 95% confident interval (CI) = 2.0-70.3, P = 0.007) and basal (OR =18.4, 95% CI = 1.8-184.7, P= 0.013) phenotypic patterns. CONCLUSIONS: The EMT markers and NOS-2 were not mortality risk factors. Basal and triple-negative phenotypic patterns were related to a higher mortality risk in patients with stage IIA tumors

Avaliação imunohistoquímica do perfil citocínico da mucosa colônica em colite experimental induzida por ácido acético

Experimental colitis induced by acetic acid has been used extensively as a model for intestinal inflammatory disease. Colonic tissue lesions of intestinal inflammatory disease patients seem to be related to the increased local production of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha, and IFN-gamma). PURPOSE: To assess the cytokine expression pattern identified through immunohistochemistry in colonic mucosa after experimental colitis induced by acetic acid and establish the relationship between this pattern and the presence of macroscopic lesions. MATERIALS AND METHODS: Adult male Wistar rats (n = 39) were divided at random into 4 groups: NC45 and NC24 (control without colitis; sacrificed at 45 minutes and 24 hours, respectively); and WC45 and WC24 (with experimental colitis induced by acetic acid; sacrificed at 45 minutes and 24 hours, respectively). Macroscopic and microscopic alterations in colonic tissue were evaluated, and cytokine expression was assessed through immunohistochemistry. RESULTS: After 24 hours, IL-1 expression was greater in the groups with colitis when compared to the groups without colitis. IL-4 expression was higher in the WC45 group. There was an increase in both INF-gamma and IL-6 related to the presence of necrosis of the colonic mucosa in the groups with colitis for both periods evaluated. CONCLUSION: The immunohistochemical technique was efficient for the analysis of various cytokine expressions in the colonic tissue. There was an increase in the IL-1 pro-inflammatory cytokines as well as in IL-6 and IFN-gamma associated with the presence of colonic necrosis. Experimental colitis induced by acetic acid is a useful model for the development of studies assessing the role of cytokines in the inflammation of mucosa as well as anti-cytokine therapies.O modelo de colite experimental induzida por ácido acético (CEAA) vem sendo extensamente utilizado em estudos sobre doenças inflamatórias intestinais (DII). Lesões no tecido colônico em portadores de DII parecem estar relacionados à produção local aumentada de citocinas pró-inflamatórias (IL-1, IL-6, TNF-alfa e IFN-gama). OBJETIVO: Avaliar o padrão de expressão de citocinas identificadas por imunohistoquímica em tecido colônico após CEAA e relacioná-lo à presença de lesões macroscópicas. MATERIAL E MÉTODOS: Ratos machos Wistar adultos (n=39) foram submetidos ou não à CEAA e sacrificados para retirada do tecido colônico em dois períodos distintos, perfazendo 4 grupos aleatórios: SC45 e SC24 (sem colite; sacrifício 45 minutos e 24 horas, respectivamente); CC45 e CC24 (com colite; sacrifício 45 minutos e 24 horas, respectivamente). Avaliaram-se alterações macro e microscópicas do cólon e sua expressão de citocinas foi avaliada por imunohistoquímica. RESULTADOS: Após 24 horas, a expressão de IL-1 foi maior no grupo com colite, em relação ao sem colite. IL-4 foi mais expressa no grupo CC45. Houve aumento de INF-gama e IL-6, relacionados à presença de necrose da mucosa colônica, nos grupos com colite, em ambos os períodos avaliados. CONCLUSÃO: A técnica de imunohistoquímica foi eficiente para a análise da expressão de citocinas na mucosa colônica. Houve aumento da expressão das citocinas pró-inflamatórias IL-1 e de IL-6 e IFN-gama associado à presença de necrose colônica. A CEAA é um bom modelo para o desenvolvimento de estudos destinados a avaliar o papel das citocinas na inflamação da mucosa e terapias anti-citocinas

Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy

<p>Abstract</p> <p>Background</p> <p>Phagocytosis of apoptotic cells by macrophages induces a suppressor phenotype. Previous data from our group suggested that this occurs via Platelet-activating factor receptor (PAF-R)-mediated pathways. In the present study, we investigated the impact of apoptotic cell inoculation or induction by a chemotherapeutic agent (dacarbazine, DTIC) on tumour growth, microenvironmental parameters and survival, and the effect of treatment with a PAF-R antagonist (WEB2170). These studies were performed in murine tumours: Ehrlich Ascitis Tumour (EAT) and B16F10 melanoma.</p> <p>Methods</p> <p>Tumour growth was assessed by direct counting of EAT cells in the ascitis or by measuring the volume of the solid tumour. Parameters of the tumour microenvironment, such as the frequency of cells expressing cyclo-oxygenase-2 (COX-2), caspase-3 and galectin-3, and microvascular density, were determined by immunohistochemistry. Levels of vascular endothelium growth factor (VEGF) and prostaglandin E2 (PGE2) were determined by ELISA, and levels of nitric oxide (NO) by Griess reaction. PAF-R expression was analysed by immunohistochemistry and flow cytometry.</p> <p>Results</p> <p>Inoculation of apoptotic cells before EAT implantation stimulated tumour growth. This effect was reversed by <it>in vivo </it>pre-treatment with WEB2170. This treatment also reduced tumour growth and modified the microenvironment by reducing PGE2, VEGF and NO production. In B16F10 melanoma, WEB2170 alone or in association with DTIC significantly reduced tumour volume. Survival of the tumour-bearing mice was not affected by WEB2170 treatment but was significantly improved by the combination of DTIC with WEB2170. Tumour microenvironment elements were among the targets of the combination therapy since the relative frequency of COX-2 and galectin-3 positive cells and the microvascular density within the tumour mass were significantly reduced by treatment with WEB2170 or DTIC alone or in combination. Antibodies to PAF-R stained the cells from inside the tumour, but not the tumour cells grown <it>in vitro</it>. At the tissue level, a few cells (probably macrophages) stained positively with antibodies to PAF-R.</p> <p>Conclusions</p> <p>We suggest that PAF-R-dependent pathways are activated during experimental tumour growth, modifying the microenvironment and the phenotype of the tumour macrophages in such a way as to favour tumour growth. Combination therapy with a PAF-R antagonist and a chemotherapeutic drug may represent a new and promising strategy for the treatment of some tumours.</p

p53 in epidermoid cancer of the esophagus

BACKGROUND/AIMS: Wild type p53 protein has an inhibitory effect on cell proliferation and transformation. Mutation or deletion of the p53 gene can be the first point of malignancy, Abnormalities of the p53 protein gene have been linked with tumors of the esophagus.METHODOLOGY: In this study, we investigated the expression of the p53 gene in epidermoid carcinoma of the esophagus as well as in the basal layer near the tumor. We studied the expression of p53 in 24 esophageal tumors and in normal esophageal tissue near the tumor in 16 cases, using an immunohistochemical reaction.RESULTS: p53 Was positive in 18 esophageal tumors (75%) and in 15 of the 16 (94%) normal samples of esophageal tissue. There was no correlation between expression of the p53 gene and age, sex, tobacco intake, alcoholism, and familiar history of cancer or clinical stage of the disease. The mean survival of the p53 patients (negative or positive) was similar.CONCLUSIONS: p53 Accumulation was found in most cases of esophageal cancer as well as in samples of normal tissue close to the tumor. The positivity of p53 seems to be independent of clinical or pathological parameters and was not of any use in predicting prognosis in our study.UNIFESP EPM, Div Gastroenterol, Discipline Gastroenterol, BR-04023000 Sao Paulo, BrazilUNIFESP EPM, Dept Pathol, BR-04023000 Sao Paulo, BrazilUNIFESP EPM, Div Gastroenterol, Discipline Gastroenterol, BR-04023000 Sao Paulo, BrazilUNIFESP EPM, Dept Pathol, BR-04023000 Sao Paulo, BrazilWeb of Scienc

Expressão do p53 no carcinoma epidermóide do lábio

OBJETIVO: Verificar o valor da expressão do p53 no carcinoma epidermóide (CEC) de lábio. MÉTODO: O estudo imunohistoquímico foi feito em material fixo em formol e mantido em bloco de parafina, corado com anticorpos anti-p53, segundo técnica da Streptavidina-Biotina-Peroxidase. Para análise estatística, foi empregado o teste de Fisher para a diferenciação de grupos em relação às variáveis do estudo. RESULTADOS: A expressão do p53 foi positiva em 87,5% do CEC bem diferenciado, 60% no moderadamente diferenciado e 91,67% no pouco diferenciado. Nas margens de ressecção cirúrgica foi negativa em 94,23% e positiva em 5,77%, havendo associação entre o grau de diferenciação e a expressão do p53 (p=0,05). CONCLUSÃO: A expressão do p53 foi positiva na lesão primária e negativa na margem de ressecção cirúrgica, mas não é determinante de mudanças no paradigma cirúrgico

Análise imuno-histoquímica das sintases do óxido nítrico em adenocarcinomas gástricos Immunohistochemical expression of nitric oxide synthases in gastric adenocarcinomas

INTRODUÇÃO: O óxido nítrico (NO) é uma molécula mediadora de diversas funções, tais como vasodilatação, neurotransmissão e metabolismo do ferro. Os efeitos do NO na biologia tumoral são ambíguos e complexos. A atividade das sintases do óxido nítrico (NOS) tem sido demonstrada em diversos tumores humanos. OBJETIVO: Pesquisar a expressão das isoformas das NOS em carcinomas gástricos e correlacionar estes achados com características demográficas e histopatológicas destes tumores. MATERIAL E MÉTODOS: O estudo imuno-histoquímico das NOS (NOS-1, NOS-2 e NOS-3) foi realizado em 128 casos de carcinomas gástricos classificados de acordo com o sistema de Lauren. RESULTADOS: A positividade para NOS-1 foi detectada em 92/128 (70%) dos casos, para NOS-2 em 36/128 (30%) e para NOS-3 em 54/128 (42%) dos casos. Na análise estatística observou-se correlação com o tipo intestinal e expressão de NOS-3, e tumores avançados mostraram maior expressão de NOS-2. CONCLUSÃO: Os carcinomas gástricos mostram expressão das três isoformas de NOS, sendo as NOS constitutivas presentes em maior número de casos. A freqüente expressão de NOS induzida nos carcinomas gástricos avançados sugere uma participação de NOS na progressão e na disseminação tumoral na mucosa gástrica.<br>INTRODUCTION: Nitric oxide is an important bioactive and signaling molecule that mediates a diverse array of actions such as vasodilatation, neurotransmission, and iron metabolism. Also, it can act as a carcinogen. Recent studies have examined the expression and activity of the NOS isoforms in several human cancers. OBJECTIVES: To investigate the expression of nitric oxide synthases in gastric carcinomas and correlate the results. MATERIAL AND METHODS: The immunohistochemistry expression of constitutive and inducible nitric oxide synthases (NOS-1, NOS-2 e NOS-3) were evaluated in 128 cases of gastric cancer classified according to Lauren system. RESULTS: The rate of expression of NOS-1 was 92 (70%) of the 12 cases, NOS-2 was 36 (30%) and NOS-3 was 54 (42%) of the cases. The expression of NOS-3 was associated with the intestinal type of carcinoma and deeply invasive tumors showed high rate of expression of NOS-2. CONCLUSION: There is high expression of all the isoforms of nitric oxide synthases in gastric cancer; the constitutive isoforms show higher expression than the inducible forms. The high expression of the inducible form in deeply invasive tumors is related with tumoral progression and dissemination in the gastric mucosa

Is the Expression of Inducible (iNOS) and Endothelial (eNOS) Nitric Oxide Synthases an Early Event in Breast Carcinogenesis?

Hosp Canc, Med & Res Ctr, Dept Breast Surg, São Paulo, BrazilHosp Canc, Med & Res Ctr, Dept Anat Pathol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Gynaecol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Gynaecol, São Paulo, BrazilWeb of Scienc

P53 overexpression in epidermoid carcinoma of the head and neck

The theory of field cancerization in tumors of the head and neck reflects the complex oncogenesis that occurs in this region. The mechanisms that control cell proliferation at the molecular level in epidermoid carcinomas (ECs) of the upper aerodigestive tract are still unclear. Mutations in p53 are the genetic alterations most often detected in ECs of the head and neck and seem to contribute actively to the carcinogenic process triggered by p53 as a tumor-suppressor gene and to its association with tobacco. The objective of the present study was to investigate the expression of p53 protein in epidermoid head and neck carcinomas by immunohistochemistry and its immunohistochemical correlation with other prognostic factors. The study was conducted on 63 consecutive ECs cases not submitted to previous treatment. Specimens of the tumor and of the normal adjacent mucosa were collected during surgery and submitted to immunohistochemical reaction for the determination of the expression of anti-protein p53 antibody (M7001 DAKO A/S, Denmark). Anatomo-clinical and demographic data were not significantly correlated with the presence of lymph node metastases or p53 expression in the tumor or in the adjacent normal mucosa. Tumor localization in the larynx was significantly correlated with p53 expression. Histological grading as grades I, II, Ill and IV was correlated with significant p53 expression (p = 0.025). Conclusions: 1) in the studied material obtained from 63 cases of head and neck ECs, we detected a 48 percent rate of immunohistochemically detectable p53 overexpression; 2) we did not detect a relationship between demographic patient data and p53 expression in the tumor or in the normal adjacent mucosa; 3) p53 overexpression was significantly more frequent in ECs material from the larynx; and 4) The presence of 12 cases with p53 overexpression in the normal adjacent mucosa and with a p53-negative tumor is in agreement with the theory of field cancerization. Follow-up of this patient series for a longer period of time will permit a better analysis of these values